These latter results suggest disparate signaling pathways activated in ccRCC and pRCC, respectively, and provide rationale for exploring targeting these signaling cascades as a therapeutic intervention in these RCC subtypes. This evidence concerns the gene PRCC and renal cell carcinoma.